A soluble needle (100) for hair transplantation, wherein the soluble needle (100) comprises a fixing plate (30) and a plurality of micro-needles (20) made of water-soluble polymers arranged on the fixing plate (30), wherein each of said micro-needle (20) comprises a needle wall (21) to penetrate scalps and a needle cavity (22) confined by the needle wall (21) and configured for accommodating a hair follicle. A method of manufacturing a soluble needle (100) for hair transplantation, wherein the method includes: dissolving water-soluble polymers in water to prepare a molding solution (S101); delivering the molding solution into a mold (S102); letting the molding solution settle in the mold to shape (S103); and separating and removing the mold to produce the soluble needle (S104). The soluble needle (100) effectively shortens the time of surgery, reduces the pain of the patients, and increases the viability rate of transplanted hair follicles.

A soluble needle (100) for hair transplantation, wherein the soluble needle (100) comprises a fixing plate (30) and a plurality of micro-needles (20) made of water-soluble polymers arranged on the fixing plate (30), wherein each of said micro-needle (20) comprises a needle wall (21) to penetrate scalps and a needle cavity (22) confined by the needle wall (21) and configured for accommodating a hair follicle. A method of manufacturing a soluble needle (100) for hair transplantation, wherein the method includes: dissolving water-soluble polymers in water to prepare a molding solution (S101); delivering the molding solution into a mold (S102); letting the molding solution settle in the mold to shape (S103); and separating and removing the mold to produce the soluble needle (S104). The soluble needle (100) effectively shortens the time of surgery, reduces the pain of the patients, and increases the viability rate of transplanted hair follicles.

An object of the present invention is to find a useful means for removing an intraocular membrane. The present invention relates to an agent for use in intraocular membrane peeling surgery, which contains a solution containing a hydrogel-forming material and satisfies the following formula 1 with respect to the dynamic viscoelasticity measured at a temperature of 25 to 40° C. and a frequency of 1 Hz.

0<V.sub.max≤3  (Formula 1)

Provided that in the formula 1, V.sub.max (Pa/sec) is the maximum change rate of the storage elastic modulus after the initiation of gelation.

The present invention relates to formulations for administration to a joint fat pad of a subject, and to methods of treating joint pain, inflammation or disease. The disclosed formulations are intended for local administration to the joint fat pad to provide sustained release of a therapeutic agent to the joint cavity and surrounding tissues. The joint may be an arthritic joint, an injured joint or a surgically replaced joint. The therapeutic agent may be an analgesic agent, an anti-inflammatory agent or an immunosuppressive agent. A single administration of the formulation to the joint fat pad delivers a therapeutically effective amount of the therapeutic agent with reduced systemic exposure relative to a single systemic or a single intra-articular administration of a therapeutic dose of an identical therapeutic agent.

The present invention relates to formulations for administration to a joint fat pad of a subject, and to methods of treating joint pain, inflammation or disease. The disclosed formulations are intended for local administration to the joint fat pad to provide sustained release of a therapeutic agent to the joint cavity and surrounding tissues. The joint may be an arthritic joint, an injured joint or a surgically replaced joint. The therapeutic agent may be an analgesic agent, an anti-inflammatory agent or an immunosuppressive agent. A single administration of the formulation to the joint fat pad delivers a therapeutically effective amount of the therapeutic agent with reduced systemic exposure relative to a single systemic or a single intra-articular administration of a therapeutic dose of an identical therapeutic agent.

An hydrogel comprising chitosan and two weak bases having different pKb values. In some embodiments, one of the weak bases if sodium hydrogen carbonate (SHC). Also, use of the hydrogel in medical and cosmetic treatments.

A soluble needle (100) for hair transplantation, wherein the soluble needle (100) comprises a fixing plate (30) and a plurality of micro-needles (20) made of water-soluble polymers arranged on the fixing plate (30), wherein each of said micro-needle (20) comprises a needle wall (21) to penetrate scalps and a needle cavity (22) confined by the needle wall (21) and configured for accommodating a hair follicle. A method of manufacturing a soluble needle (100) for hair transplantation, wherein the method includes: dissolving water-soluble polymers in water to prepare a molding solution (S101); delivering the molding solution into a mold (S102); letting the molding solution settle in the mold to shape (S103); and separating and removing the mold to produce the soluble needle (S104). The soluble needle (100) effectively shortens the time of surgery, reduces the pain of the patients, and increases the viability rate of transplanted hair follicles.

A soluble needle (100) for hair transplantation, wherein the soluble needle (100) comprises a fixing plate (30) and a plurality of micro-needles (20) made of water-soluble polymers arranged on the fixing plate (30), wherein each of said micro-needle (20) comprises a needle wall (21) to penetrate scalps and a needle cavity (22) confined by the needle wall (21) and configured for accommodating a hair follicle. A method of manufacturing a soluble needle (100) for hair transplantation, wherein the method includes: dissolving water-soluble polymers in water to prepare a molding solution (S101); delivering the molding solution into a mold (S102); letting the molding solution settle in the mold to shape (S103); and separating and removing the mold to produce the soluble needle (S104). The soluble needle (100) effectively shortens the time of surgery, reduces the pain of the patients, and increases the viability rate of transplanted hair follicles.

Devices, systems, and methods are provided including a structure having one or more surfaces configured for internal use within a patient's body and one or more therapeutic compositions comprising one or more active substances including a direct factor Xa inhibitor, and a direct factor IIa inhibitor disposed in or on the structure. The structure is configured to be positioned adjacent an injury site in the patient's body. The one or more active substances optionally include an anti-proliferative agent. The therapeutic composition is formulated to release the one or more active substances to the injury site to provide one or more of inhibit clot formation, promote clot dissolution, inhibit or dissolute inflammation, inhibit vessel injury, increase time before clotting, and/or inhibit cell proliferation.

The method, characterized in that, the powdered chitosan is dissolved in water to obtain a 5% solution, into which a 70-90% acetic acid is added and after the formation of the blank intramedullary nail and carrying a coagulating bath and neutralization bath it is subjected to a crosslinking bath in a solution formed from 0.5 to 2% of sodium tri-polyphosphate and 0.5% to 3% Na3PO4 for 24 to 48 hours in temperature of 50° C. to 140° C. and then it is subjected to the drying process, for a period of 6 to 10 days, and finally the surface of the blank is treated to form the intramedullary nail. The surface treatment is carried out until the surface of the intramedullary nail contains at least 20%-40% of the pore of the depth of 0.1 mm to 1 mm.